Clinical Trials Browser

Recurrence × selinexor × Gynecologic × Clear all

NCT05983276 2024-02-08

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence